New Zealand markets closed

Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
18.13-0.53 (-2.84%)
At close: 03:04PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 5.37B
Enterprise value 3.60B
Trailing P/E 31.10
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.88
Price/book (mrq)2.24
Enterprise value/revenue 5.92
Enterprise value/EBITDA 18.03

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-26.15%
S&P500 52-week change 326.43%
52-week high 331.56
52-week low 314.05
50-day moving average 317.76
200-day moving average 321.11

Share statistics

Avg vol (3-month) 33.91M
Avg vol (10-day) 34.72M
Shares outstanding 5288M
Implied shares outstanding 6291.05M
Float 8150.45M
% held by insiders 175.44%
% held by institutions 10.69%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.4
Forward annual dividend yield 42.14%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 466.67%
Dividend date 3N/A
Ex-dividend date 431 May 2023
Last split factor 21.2:1
Last split date 331 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 28.56%
Operating margin (ttm)18.79%

Management effectiveness

Return on assets (ttm)3.44%
Return on equity (ttm)7.37%

Income statement

Revenue (ttm)607.8M
Revenue per share (ttm)2.10
Quarterly revenue growth (yoy)-28.60%
Gross profit (ttm)N/A
EBITDA 158.45M
Net income avi to common (ttm)173.57M
Diluted EPS (ttm)0.60
Quarterly earnings growth (yoy)-6.40%

Balance sheet

Total cash (mrq)1.78B
Total cash per share (mrq)6.2
Total debt (mrq)5.92M
Total debt/equity (mrq)0.25%
Current ratio (mrq)15.47
Book value per share (mrq)8.33

Cash flow statement

Operating cash flow (ttm)167.15M
Levered free cash flow (ttm)-150.6M